Balance Sheet

Cash Flow Statement

Amortization Amortization Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Profound Medical (PROF) Other financing activities (2024 - 2026)

Profound Medical has reported Other financing activities over the past 2 years, most recently at -$1.0 million for Q3 2025.

For Q3 2025, Other financing activities fell 1380.0% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached $1.8 million, changed N/A, while the annual FY2025 figure was $1.0 million, 79.24% down from the prior year.
Other financing activities for Q3 2025 was -$1.0 million at Profound Medical, down from -$89000.0 in the prior quarter.
Over five years, Other financing activities peaked at $3.0 million in Q4 2024 and troughed at -$1.0 million in Q3 2025.